Noble Financial Thinks TrovaGene’s Stock is Going to Recover


In a report released yesterday, Ahu Demir from Noble Financial maintained a Buy rating on TrovaGene (TROV), with a price target of $5. The company’s shares opened today at $2.85, close to its 52-week low of $2.54.

According to TipRanks.com, Demir is ranked #3833 out of 5188 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TrovaGene with a $4 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.20 and a one-year low of $2.54. Currently, TrovaGene has an average volume of 346.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts